Evaluating the mucoprotective effects of glycyrrhizic acid-loaded polymeric nanoparticles in a murine model of 5-fluorouracil-induced intestinal mucositis via suppression of inflammatory mediators and oxidative stress

Inflammopharmacology. 2021 Oct;29(5):1539-1553. doi: 10.1007/s10787-021-00866-z. Epub 2021 Aug 22.

Abstract

Objectives: 5-Fluorouracil (5-FU), a chemotherapeutic drug, has severe deteriorating effects on the intestine, leading to mucositis. Glycyrrhizic acid is a compound derived from a common herbal plant Glycyrrhiza glabra, with mucoprotective, antioxidant and anti-inflammatory actions, however, associated with poor pharmacokinetics. Owing to the remarkable therapeutic action of glycyrrhizic acid-loaded polymeric nanocarriers in inflammatory bowel disease, we explored their activity against 5-FU-induced intestinal mucositis in mice. Polymeric nanocarriers have proven to be efficient drug delivery vehicles for the long-term treatment of inflammatory diseases, but have not yet been explored for 5-FU-induced mucositis. Therefore, this study aimed to produce glycyrrhizic acid-loaded polylactic-co-glycolic acid (GA-PLGA) nanoparticles to evaluate their protective and therapeutic effects in a 5-FU-induced mucositis model.

Methods: GA-PLGA nanoparticles were prepared using a modified double emulsion method, physicochemically characterized, and tested for in vitro drug release. Thereafter, mucositis was induced by 5-FU (50 mg/kg; IP) administration to the mice for the first 3 days (day 0, 1, 2), and mice were treated orally with GA-PLGA nanoparticles for 7 days (day 0-6).

Results: GA-PLGA nanoparticles significantly reduced mucositis severity measured by body weight, diarrhea score, distress, and anorexia. Further, 5-FU induced intestinal histopathological damage, altered villi-crypt length, reduced goblet cell count, elevated pro-inflammatory mediators, and suppressed antioxidant enzymes, all of which were reversed by GA-PLGA nanoparticles.

Conclusion: Morphological, behavioral, histological, and biochemical results suggested that GA-PLGA nanoparticles were efficient, biocompatible, targeted, and sustained release drug delivery nano-vehicle for enhanced mucoprotective, anti-inflammatory, and antioxidant effects in 5-FU-induced intestinal mucositis.

Keywords: 5-Fluorouracil; Glycyrrhizic acid; Intestinal mucositis; Oral drug delivery; Oxidative stress; Polymeric nanoparticles.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology
  • Antimetabolites, Antineoplastic / toxicity
  • Antioxidants / administration & dosage
  • Antioxidants / pharmacology
  • Drug Carriers / chemistry
  • Fluorouracil / toxicity*
  • Glycyrrhizic Acid / administration & dosage
  • Glycyrrhizic Acid / pharmacology*
  • Inflammation Mediators / metabolism
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / pathology
  • Mice
  • Mice, Inbred BALB C
  • Mucositis / chemically induced
  • Mucositis / prevention & control*
  • Nanoparticles*
  • Oxidative Stress / drug effects
  • Polylactic Acid-Polyglycolic Acid Copolymer / chemistry

Substances

  • Anti-Inflammatory Agents
  • Antimetabolites, Antineoplastic
  • Antioxidants
  • Drug Carriers
  • Inflammation Mediators
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Glycyrrhizic Acid
  • Fluorouracil